In Page Content
- Take advantage of our unmatched expertise across all ingredient categories
- Navigate Every Stage of Your Novel Food Application With Confidence
- Benefits of Novel Food Consulting With FoodChain ID
- Success Stories
- More Ways to Strengthen Your Supplements and Novel Food Strategy
- Resources from our Experts
- FAQ
- Request a Novel Food Consultation
Take advantage of our unmatched expertise across all ingredient categories
Novel food applications developed by scientific and regulatory experts behind two decades of EFSA authorizations.
20+
Years of Novel Food Regulatory & Scientific Expertise
How it Works
Navigate Every Stage of Your Novel Food Application With Confidence
Step 1
Dossier submission
Your Novel Food application, built on solid compositional, toxicological and exposure data, is submitted to the European Commission for validation.
Step 2
EFSA risk assessment
The European Food Safety Authority evaluates the safety of the ingredient. We manage every clarification request to keep the clock moving.
Step 3
EFSA scientific opinion
EFSA publishes its opinion on the safety of the novel food, and makes proposition on the conditions of use of the ingredient.
Step 4
European Commission & Member State vote
The Commission drafts an implementing regulation, submitted to Member States for a vote within the Standing Committee.
Step 5
Market authorization
The regulation is published in the official journal of the EU and the ingredient is added to the Union list of novel food, ready to market
From Ingredient to Authorized Novel Food
Benefits of Novel Food Consulting With FoodChain ID
Regulatory Strategy & Classification
Confirm your Novel Food status before you invest
Avoid costly missteps with an early, accurate determination of your ingredient’s regulatory pathway
Scientific Dossier Preparation
Build an EFSA-ready dossier the first time
Structure toxicology, compositional and exposure data to meet EFSA’s technical guidance and limit requests for extra information
EFSA Liaison & Risk Assessment Support
Respond to EFSA questions with confidence
Our scientists manage clarification requests and risk assessment discussions to keep your file moving
Multi-Market Regulatory Alignment
Extend authorization beyond the EU
Leverage your EU Novel Food dossier to support parallel filings in the UK, US and other markets
Data Protection Strategy
Protect years of research investment
Secure proprietary data protection so your innovation isn’t opened to competitors for five years
End-to-End Project Management
One dedicated team, start to finish
A single point of contact guides your project from ingredient assessment through Official Journal publication
Success Stories
Extend Your Regulatory Capabilities
More Ways to Strengthen Your Supplements and Novel Food Strategy
FoodChain ID’s Novel Food dossier experts work alongside our broader Health & Nutrition Consulting, R&D and Compliance solutions so ingredient innovation stays connected from formulation through EU authorization and beyond.
Resources from our Experts



FAQ
Foods that were not consumed ‘to a significant degree’ in the EU before 15 May 1997 require an application for use. These foods must be safe for human consumption, and not mislead the customer in relation to nutritional value if there is the intention that this food will replace another.
The application requires:
A complete description of the manufacturing process, safety protocols, and certifications
A full analysis of the ingredient
A calculation of human exposure (mean and 95th percentile exposure)
Genotoxicity testing (a minimum of 2 studies)
A 90-day sub-chronic toxicity study
An evaluation of the potential allergenicity (if the ingredient contains proteins)
Unfortunately, the novel foods application process is very technical and requires expertise and time that’s not often available within an organization. Relying on our team of experts to assist with this process allows your team to focus on other objectives. Our knowledge of—and experience in—novel food applications ensures your application will meet all the regulatory requirements that EFSA and the European Commission need to approve your submission.
At FoodChain ID we work with you to select the right service for your product, from regulatory analysis to a consultation process and any submissions or follow-ups with EFSA. This removes the strain from your business, it allows budget to be made available for other projects.
From start to finish, using an expert to support your novel food application means you benefit from the knowledge we have gained from our years of experience.
In the European Union, a Novel Food (NF) is defined as any food that was not consumed to a significant degree by humans within the Union before May 15, 1997. The regulation of NFs, primarily under Regulation (EU) 2015/2283, aims to ensure the safety of new food products before they enter the market. This framework is crucial for integrating innovative food items into existing food systems, particularly as society seeks more sustainable, functional, and health-promoting options.
The average duration of a Novel Food application from initial submission to the publication of the European Food Safety Authority (EFSA) opinion is approximately 2 years and half, with a large variability depending on the ingredient characteristics and data availabilities. While EFSA should last only 9 months, the additional data request from authorities extends the process for several months, with finally a scientific evaluation lasting almost 2 years. Our team helps to reduce the timeline, by anticipating potential gaps in the available evidence, and by managing efficiently any request from authorities.
Significant delays in the Novel Food authorization process are often attributed to:
Suitability Checks and EC Validation: Administrative steps like EFSA’s suitability check and European Commission (EC) validation can take nearly a year, with high variability due to inconsistent dossier quality and procedural inefficiencies.
Additional Data Requests (ADRs): EFSA frequently issues ADRs to applicants, which significantly extend timelines. These requests, averaging 2.7 per application, often pertain to production processes, compositional data, and toxicological assessments. Applicants take an average of 130 days to respond to each ADR, with the cumulative response time accounting for nearly half of the total scientific evaluation period.
Transparency Regulation (EU) 2019/1381: Implemented in 2021, this regulation introduced additional obligations, such as mandatory notification of studies, leading to application rejections (30 applications were rejected due to non-compliance) and increased complexity.
Updated Scientific Guidance: While intended to provide clarity, the 2021 and 2024 updates to EFSA’s scientific guidance have also introduced more stringent requirements, potentially adding to the burden on applicants.
The current EU Novel Food regulatory framework significantly delays market access for innovative food products, potentially hindering innovation across the food sector. The lengthy and sometimes inconsistent evaluation procedures can discourage applicants, particularly small and medium-sized enterprises, from engaging with the regulatory process. These delays can lead to the failure of food businesses by extending market access timelines beyond what is sustainable. Moreover, it limits consumer choice and access to beneficial food products, which is problematic when global challenges like sustainability, economic competitiveness, and evolving dietary needs require prompt solutions. The process is perceived as a disincentive for investment and entrepreneurial experimentation.
Despite the procedural challenges and lengthy timelines, the European Food Safety Authority (EFSA) has a high rate of positive opinions for Novel Food applications. An analysis from our experts showed an overall positive opinion rate greater than 85% when considering all application submitted pursuant to the current novel food regulation. The main reasons for rejection were safety concerns, inability to identify the source of the novel food, and poor application quality or lack of pertinent responses from the applicant.
The EU’s regulatory landscape for Novel Foods is recognized as one of the most rigorous globally. However, this rigor, combined with the lengthy authorization timelines, means that sustainable alternatives like plant-based proteins, fungal biomasses, and cellular meat—which are already approved in other regions—remain largely inaccessible in the EU due to pending regulatory approvals. This regulatory lag poses a risk to the competitiveness of the European food industry and its ability to adapt to evolving societal demands for sustainable food systems, such as those promoted by the Farm to Fork Strategy. The delay in authorizing new food ingredients, even those derived from valorized agri-food waste, can impede the rapid adoption of eco-friendly practices.
The Transparency Regulation (EU) 2019/1381, implemented in 2021, has notably impacted the Novel Food authorization process. It imposes additional regulatory obligations on food business operators, most significantly the mandatory notification of studies prior to submitting an application. Failure to comply with these requirements can lead to the outright rejection of applications by authorities. This adds a layer of complexity and risk to an already rigorous process.
To improve the efficiency of the EU’s Novel Food evaluation process while maintaining high safety standards, several recommendations are put forth:
– Improved Guidelines and Pre-submission Support: Providing clearer guidance and enhanced pre-submission dialogue for applicants could streamline the process and improve dossier quality, reducing the need for Additional Data Requests (ADRs).
– Streamlined Risk Assessments: Implementing more robust upstream risk assessments could reduce the number of dossiers systematically referred to EFSA by the European Commission, allowing EFSA to focus on more complex or truly novel evaluations.
– Balancing Rigor and Efficiency: Policymakers need to critically reassess the procedural design to balance scientific rigor with regulatory efficiency.
– Addressing Bottlenecks: Identifying and addressing administrative bottlenecks, particularly in the suitability check and validation phases, is crucial to reduce the overall duration of the process.-



